Category: Arch TherapeuticsSyndicate content

Baxter adds 30 jobs in Malta | Medtech personnel moves for the week of Apr. 7, 2014

April 9, 2014 by MassDevice

Here's a look at some of the top personnel stories for medical device companies this week.

Report: Baxter to add 30 jobs in Malta

April 2, 2014 by Arezu Sarvestani

Report: Baxter to add 30 jobs in Malta

Malta regulators announced this week that healthcare titan Baxter plans to add 30 additional jobs in the country.

Z-Medica taps ex-Solta Medical CEO Fanning | Personnel Moves

April 3, 2014 by Brad Perriello

Stephen Fanning, the former CEO of Solta Medical, is Z-Medica's new chief.

Z-Medica taps ex-Solta Medical CEO Fanning

Z-Medica said it named Stephen Fanning, the former CEO of Solta Medical, to be its new chief executive.

Wallingford, Conn.-based Z-Medica is developing blood clotting technologies it calls QuikClot.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Arch Therapeutics closes $2.9M funding round

February 10, 2014 by Chris Walker

Arch Therapeutics hits its $2.9 million funding goal after announcing a private stock placement late last year.

Arch Therapeutics closes $2.9M funding round

Arch Therapeutics hit its nearly $2.9 million target with a private placement announced late last year.

Arch Therapeutics offers $2.9M in private stock placement

February 7, 2014 by Chris Walker

Massachusetts-based Arch Therapeutics hopes to sell over 11 million shares to raise close to $3 million in support of its medical sealants and hemostasis products.

Arch Therapeutics brings in nearly $3M in private stock placement

Arch Therapeutics launched a private placement fundraising effort, offering 11.4 million shares of common stock in hopes of raising $2.9 million.

Arch Therapeutics completes share swap following reverse merger

July 9, 2013 by Sony Salzman

Arch Therapeutics reports a $7.3 million financing through a share-swap related to its reverse merger with Arch Biosurgery, which marked the Arch Therapeutics’ transformation into a life sciences company.

Arch Therapeutics funding round

Cambridge, Mass.-based device company Arch Therapeutics raised $7.3 million through a stock trade in connection with its reverse merger with Arch Biosurgery.

Arch Therapeutics issued shares of its common stock in exchange for cancellation of equity or rights to acquire equity in Arch Biosurgery, according to a regulatory filing.

New finance chief at Becton, Dickinson and Co. | Personnel Moves

July 9, 2013 by Sony Salzman

Breast reconstruction technology company AirXpanders is almost halfway to a hoped-for $9M funding round.

fired/hired

A new finance chief will take over on Monday at Becton Dickinson & Co. (NYSE:BDX), the company announced this week. BD nabbed Christopher Reidy from his former gig as CFO at ADP Corporation. Reidy has also worked in executive finance roles at NBA Properties Inc. and AT&T.

Arch Therapeutics shuffles leadership post-merger | Personnel Moves

July 5, 2013 by Sony Salzman

Following a reverse-merger with Arch Biosciences, Arch Therapeutics names a new CEO, board chairman and director.

fired/hired

Three fresh faces are taking over at Arch Therapeutics following the blood management device company's reverse merger with Arch Biosurgery. Last last month Arch Therapeutics turned over a new leaf as a life science company after adopting the business plan of newly acquired subsidiary Arch Biosurgery.

Shortly after closing the deal, Arch Therapeutics cleaned out its management team, appointing a new CEO, board chairman, and company director.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp